Related Experiment Video
Updated: Feb 9, 2026

Application of Robot-assisted Pancreaticobiliary Junction Resection in Benign Duodenal Tumors
Published on: December 20, 2024
Robot-assisted sacral tumor resection: a preliminary study
Junqiang Yin1, Hui Wu2, Jian Tu1
1Department of Musculoskeletal Oncology, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China.
Background:
Few studies have been done on robot-assisted sacral surgery. This study aims to evaluate the outcomes of seven patients with benign sacral or presacral tumors treated with a robotic surgical system at a single center.
Methods:
All patients with benign sacral or presacral tumors who underwent transperitoneal resection (between June 2015 and June 2016) using the da Vinci Si HD robotic surgical system (Intuitive Surgical Inc.) were included in this retrospective study.
Results:
Seven patients with a mean age of 43.8 years (range: 22- 62 years) were included in this study. The operation time ranged from 60 to 335 min. Five out of these seven patients with presacral tumor underwent complete tumor resection by the da Vinci robotic surgical system, with a median blood loss of 52 ml. The other patients underwent excision of the presacral tumor by the da Vinci robotic surgical system, followed by a posterior approach, with a median blood loss of 675 ml. The histological diagnosis was schwannoma of the sacral nerve in five cases (71.5%). The other two cases were chordoma and solitary fibroma of the sacrum, respectively. No perioperative or postoperative complications were encountered. The average hospitalization stay was 5.7 days. No recurrences were found at follow-up 24 to 31 months later.
Conclusion:
Robot-assisted minimally invasive sacral surgery can provide precise dissection of the tissue under a perfect view. It is a technically feasible procedure that is associated with minimal blood loss, fewer injuries and short hospitalization. It is particularly suitable for presacral benign tumors.
Insights
Robot-assisted surgery for benign sacral tumors offers precise dissection and minimal blood loss. This minimally invasive approach is technically feasible, leading to shorter hospital stays and no recurrences in a small patient cohort.
Area of Science:
- Minimally Invasive Surgery
- Surgical Robotics
- Oncology
Background:
- Limited research exists on robot-assisted sacral surgery.
- This study evaluates outcomes for benign sacral/presacral tumors using robotic assistance.
Purpose of the Study:
- To assess the efficacy and safety of robot-assisted minimally invasive sacral surgery.
- To evaluate outcomes in patients with benign sacral or presacral tumors.
Main Methods:
- Retrospective study of seven patients with benign sacral/presacral tumors.
- Procedures performed between June 2015 and June 2016 using the da Vinci Si HD robotic surgical system.
- Transperitoneal resection was the primary surgical approach.
Main Results:
- Mean patient age was 43.8 years; operation time varied (60-335 min).
- Median blood loss was 52 ml for complete resections and 675 ml for combined approaches.
- Histological diagnoses included schwannoma (5 cases), chordoma (1), and solitary fibroma (1). No complications or recurrences were observed during follow-up (24-31 months).
Conclusions:
- Robot-assisted sacral surgery enables precise dissection with excellent visualization.
- The procedure is technically feasible, associated with minimal blood loss, fewer injuries, and short hospitalization.
- This approach is particularly beneficial for benign presacral tumors.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
The Tumor Microenvironment
Case Studies
Matrix-Assisted Laser Desorption Ionization (MALDI)
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

